CEVIMELINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cevimeline Hydrochloride, and what generic alternatives are available?
Cevimeline Hydrochloride is a drug marketed by Apotex Inc, Aurobindo Pharma, Bionpharma, Hikma, Novel Labs Inc, Rising, and Rubicon. and is included in seven NDAs.
The generic ingredient in CEVIMELINE HYDROCHLORIDE is cevimeline hydrochloride. There are four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cevimeline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cevimeline Hydrochloride
A generic version of CEVIMELINE HYDROCHLORIDE was approved as cevimeline hydrochloride by HIKMA on July 8th, 2013.
Summary for CEVIMELINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 88 |
Clinical Trials: | 6 |
Patent Applications: | 63 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in CEVIMELINE HYDROCHLORIDE? | CEVIMELINE HYDROCHLORIDE excipients list |
DailyMed Link: | CEVIMELINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for CEVIMELINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
China Medical University Hospital | Phase 4 |
Roxane Laboratories | Early Phase 1 |
University of Kentucky | N/A |
Pharmacology for CEVIMELINE HYDROCHLORIDE
Drug Class | Cholinergic Receptor Agonist |
Mechanism of Action | Cholinergic Muscarinic Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for CEVIMELINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for CEVIMELINE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
EVOXAC | Capsules | cevimeline hydrochloride | 30 mg | 020989 | 1 | 2009-02-27 |